Financials

  • Market Capitalization 24.51 M
  • Employee 14
  • Founded 2016
  • CEO N/A
  • Website www.barinthusbio.com
  • Headquarter United Kingdom
  • FIGI BBG00ZZPCP09
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-0.43
Rapporto prezzo/fatturato

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.

Notizie